Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Paclitaxel

FDA-approved product (injectable, injection), marketed as Abraxane, Paclitaxel, Taxol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Paclitaxel
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Carcinoma
  • HER2 Positive Breast Carcinoma
  • Kaposi's sarcoma
  • Malignant Pancreatic Neoplasm
  • Neoplasm
  • Non-small cell lung carcinoma
  • Ovarian cancer
  • Ovarian carcinoma
  • Ovarian neoplasm
  • Pancreatic carcinoma
  • Pancreatic neoplasm
  • Undifferentiated carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Taxanes
FDA pharmacologic class
Microtubule Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae33.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Paclitaxel in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Paclitaxel with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ph II Intraperitoneal Paclitaxel + System Therapy in GI Ca w/Peritoneal Carcinomatosis (STOPGAP-B)

    NCT07795749 · start 2026-08-04

    Registered record
    Registry ID
    NCT07795749
    Conditions
    Esophageal Carcinoma; Gastric Cancer (Diagnosis); Colorectal Adenocarcinoma; Appendiceal Adenocarcinoma; Small Bowel Adenocarcinoma; Hepatobiliary Carcinoma in Situ
    Interventions
    Paclitaxel Q2W; Paclitaxcel Q3W
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-08-04
    Completion
    2029-08-31
    Enrolment
    55

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Carcinoma; Gastric Cancer (Diagnosis); Colorectal Adenocarcinoma; Appendiceal Adenocarcinoma +2 more
    InterventionPaclitaxel Q2W; Paclitaxcel Q3W
    PhasePhase 2
    Registry statusRecruiting

  • A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

    NCT07554456 · start 2026-06-09

    Registered record
    Registry ID
    NCT07554456
    Conditions
    Esophageal Squamous Cell Carcinoma
    Interventions
    BL-B01D1; Tislelizumab; 5-Fluorouracil; Cisplatin; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-06-09
    Completion
    2028-12
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Squamous Cell Carcinoma
    InterventionBL-B01D1; Tislelizumab; 5-Fluorouracil; Cisplatin +1 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer

    NCT07318883 · start 2026-03

    Registered record
    Registry ID
    NCT07318883
    Conditions
    Squamous NSCLC
    Interventions
    HLX07; HLX07 placebo; Serplulimab; Pembrolizumab; Carboplatin; Paclitaxel or Nab-Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2031-01
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous NSCLC
    InterventionHLX07; HLX07 placebo; Serplulimab; Pembrolizumab +2 more
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

    NCT07139041 · start 2025-10

    Registered record
    Registry ID
    NCT07139041
    Conditions
    NSCLC (Non-small-cell Lung Cancer)
    Interventions
    Iparomlimab and tuvonralimab plus chemotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-10
    Completion
    2029-06
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Non-small-cell Lung Cancer)
    InterventionIparomlimab and tuvonralimab plus chemotherapy
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    NCT06946797 · start 2025-09-19

    Registered record
    Registry ID
    NCT06946797
    Conditions
    Non-Small Cell Lung Cancer
    Interventions
    Nivolumab; Ipilimumab; Carboplatin; Paclitaxel; Pemetrexed; Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2025-09-19
    Completion
    2028-10-25
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Small Cell Lung Cancer
    InterventionNivolumab; Ipilimumab; Carboplatin; Paclitaxel +2 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

    NCT07086456 · start 2025-07-20

    Registered record
    Registry ID
    NCT07086456
    Conditions
    Surufatinib; Tislelizumab; Concurrent Chemoradiotherapy; Consolidation Therapy; Non-small Cell Lung Cancer
    Interventions
    Surufatinib; Tislelizumab; Concurrent Chemotherapy; Radiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-07-20
    Completion
    2029-07-19
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSurufatinib; Tislelizumab; Concurrent Chemoradiotherapy; Consolidation Therapy +1 more
    InterventionSurufatinib; Tislelizumab; Concurrent Chemotherapy; Radiotherapy
    PhasePhase 2
    Registry statusRecruiting

  • Clinical Outcomes of Drug-Coated Balloons in the Treatment of Patients With Coronary De Novo Chronic Total Occlusion Lesions

    NCT07463664 · start 2025-04-28

    Registered record
    Registry ID
    NCT07463664
    Conditions
    Chronic Total Occlusions of Coronary Arteries; Chronic Total Occlusion (CTO); Coronary Artery Disease (CAD)
    Interventions
    DES Implantation; DCB Angioplasty
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-04-28
    Completion
    2026-12-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Total Occlusions of Coronary Arteries; Chronic Total Occlusion (CTO); Coronary Artery Disease (CAD)
    InterventionDES Implantation; DCB Angioplasty
    PhaseNot applicable
    Registry statusRecruiting

  • SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    NCT06743126 · start 2025-01-14

    Registered record
    Registry ID
    NCT06743126
    Conditions
    Melanoma, Cutaneous Malignant
    Interventions
    IMA203; nivolumab plus relatlimab; lifileucel; nivolumab; pembrolizumab; ipilimumab; Dacarbazine; temozolomide; paclitaxel; paclitaxel plus carboplatin; Albumin-Bound Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2025-01-14
    Completion
    2031-10
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMelanoma, Cutaneous Malignant
    InterventionIMA203; nivolumab plus relatlimab; lifileucel; nivolumab +7 more
    PhasePhase 3
    Registry statusRecruiting

  • Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer

    NCT06748508 · start 2024-12-25

    Registered record
    Registry ID
    NCT06748508
    Conditions
    Gastric (Stomach) Cancer
    Interventions
    Sintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-12-25
    Completion
    2027-12-25
    Enrolment
    141

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric (Stomach) Cancer
    InterventionSintilimab, oxalipaltin, 5FU,Nab-paclitaxel,lenvatinib
    PhasePhase 2
    Registry statusNot yet recruiting

  • Neoadjuvant Chemotherapy + PD-1 Inhibitor+Different Radiotherapy Fractionations for HR+/HER2- Breast Cancer

    NCT06639672 · start 2024-11-01

    Registered record
    Registry ID
    NCT06639672
    Conditions
    HR+HER2- Breast Cancer
    Interventions
    Chemotherapy+PD-1 inhibitor+8Gy x 3f; Chemotherapy+PD-1 inhibitor+16Gy x 1f; Chemotherapy+PD-1 inhibitor+2.67Gy x 15f; Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-11-01
    Completion
    2031-05-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHR+HER2- Breast Cancer
    InterventionChemotherapy+PD-1 inhibitor+8Gy x 3f; Chemotherapy+PD-1 inhibitor+16Gy x 1f; Chemotherapy+PD-1 inhibitor+2.67Gy x 15f; Chemotherapy+PD-1 inhibitor+0.5Gy x 12-18f
    PhasePhase 2
    Registry statusNot yet recruiting

  • "The Effect of Memantine on the Prevention and Amelioration of Paclitaxel-induced Toxicity in Breast Cancer Patients"

    NCT06679387 · start 2024-10-30

    Registered record
    Registry ID
    NCT06679387
    Conditions
    Breast Cancer Early Stage Breast Cancer (Stage 1-3)
    Interventions
    Memantine-HCl; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-30
    Completion
    2025-10
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Early Stage Breast Cancer (Stage 1-3)
    InterventionMemantine-HCl; Placebo Oral Tablet
    PhasePhase 2
    Registry statusRecruiting

  • Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

    NCT06323460 · start 2024-03-21

    Registered record
    Registry ID
    NCT06323460
    Conditions
    Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma
    Interventions
    Biospecimen Collection; Carboplatin; Cisplatin; Computed Tomography; External Beam Radiation Therapy; Paclitaxel; Positron Emission Tomography; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-03-21
    Completion
    2026-12-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionClinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma
    InterventionBiospecimen Collection; Carboplatin; Cisplatin; Computed Tomography +4 more
    PhasePhase 2
    Registry statusRecruiting

  • A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

    NCT05867420 · start 2023-08-02

    Registered record
    Registry ID
    NCT05867420
    Conditions
    Advanced Solid Tumors
    Interventions
    ASKG915; Paclitaxel + Bevacizumab; Fruquintinib; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-08-02
    Completion
    2028-06-30
    Enrolment
    594

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumors
    InterventionASKG915; Paclitaxel + Bevacizumab; Fruquintinib; Docetaxel
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

    NCT05595109 · start 2022-10-28

    Registered record
    Registry ID
    NCT05595109
    Conditions
    Breast Cancer; Peripheral Neuropathy; Cardiac Toxicities; Hepatic Toxicity; Cognitive Impairment
    Interventions
    Silymarin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2022-10-28
    Completion
    2024-10-28
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Peripheral Neuropathy; Cardiac Toxicities; Hepatic Toxicity +1 more
    InterventionSilymarin; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

    NCT04877821 · start 2021-09-15

    Registered record
    Registry ID
    NCT04877821
    Conditions
    Triple Negative Breast Cancer
    Interventions
    Sintilimab; Anlotinib; Nab paclitaxel; Carboplatin; Epirubicin; Cyclophosphamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2021-09-15
    Completion
    2026-03-10
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTriple Negative Breast Cancer
    InterventionSintilimab; Anlotinib; Nab paclitaxel; Carboplatin +2 more
    PhasePhase 2
    Registry statusCompleted